MedTrace Logo

Niraparib in High-grade Endometrial Cancer Trial

NCT05289648 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-12-19

No results posted yet for this study

Summary

The study will investigate the effect of niraparib on tumor tissue in chemotherapy naïve, newly diagnosed, high-grade endometrial cancer patients. Biomarkers of cognate molecular pathways as well as investigational assays will be used to study the antineoplastic effect of the drug.

Conditions

Interventions

DRUG

Niraparib oral capsule

Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days

Sponsors & Collaborators

  • Sir Mortimer B. Davis - Jewish General Hospital

    lead OTHER

Principal Investigators

  • Shannon Salvador, MD MSc · McGill University, Jewish General Hospital

  • Walter Gotlieb, MD PhD · McGill University, Jewish General Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-10-31
Completion
2026-01-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05289648 on ClinicalTrials.gov